Status:

UNKNOWN

Allergy to Neuromuscular Blocking Agents and Pholcodine Exposure

Lead Sponsor:

Central Hospital, Nancy, France

Collaborating Sponsors:

Zambon SpA

Laboratoires URGO

Conditions:

Neuromuscular Blocking Agents Anaphylaxis

Eligibility:

All Genders

2+ years

Phase:

NA

Brief Summary

The main objective of this study is to compare pholcodine exposure in patients having presented with a perianaesthetic anaphylactic reaction to a NMBA (cases) to pholcodine exposure in matched anaesth...

Eligibility Criteria

Inclusion

  • Male or female, age ≥ 2 years old.
  • Referred to anaesthesia-allergy consultation within (approximately) 6 to 12 weeks of occurrence of peranaesthetic anaphylactic reaction during anaesthesia with administration of NMBAs (only for case patient).
  • Having given his/her consent (or the 2 parents consent for minors).
  • Affiliated with a social security scheme or dependent.
  • Able to answer a medicinal product intake questionnaire
  • In a clinical condition compatible with skin tests (no skin disease or psychiatric illness, etc.) (only for case patient)
  • Having stopped any anti-histamine treatment at least 8 days previously (only for case patient).
  • With positive skin test for the suspected NMBA (ony for case patient).
  • Patient anaesthetised in a control recruitment centre (only for control patients)
  • Having undergone anaesthesia with NMBA injection, without onset of peranaesthetic anaphylactic reaction whatever his medical history (only for control patients)

Exclusion

  • Patients who have refused, or are unable to give their consent
  • Patients who have had negative control skin tests
  • Anaphylaxis suspected to be related to other drugs given on induction of anaesthesia, eg. antibiotics
  • Having presented with anaphylactic reaction during a previous anaesthesia without NMBA injection
  • Pregnant females at inclusion or during 12 months before anaesthesia

Key Trial Info

Start Date :

July 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2020

Estimated Enrollment :

1020 Patients enrolled

Trial Details

Trial ID

NCT02250729

Start Date

July 1 2014

End Date

July 1 2020

Last Update

December 27 2018

Active Locations (24)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (24 locations)

1

CHU d' ANGERS

Angers, France

2

CHU de Besançon

Besançon, France, 25030

3

CHU de Bordeaux

Bordeaux, France, 33000

4

CHU de Caen

Caen, France, 14000